The MaxCyte® STX™ Scalable Transfection System can load up to 10 billion cells (1E10) with DNA, mRNA, siRNA or proteins in less than thirty minutes, enabling drug screeners to bypass the lengthy and costly process of stable cell line development. In addition to achieving levels of transfection efficiency and viability that often exceed 90% with many commonly used cell lines, the MaxCyte STX also allows efficient transfection of primary cells, allowing scientists to develop more biologically relevant cell-based assays.

In this presentation, we will give an overview of the MaxCyte STX technology, provide examples of target molecule loading in primary cells, and present case studies of cell-based assay development using the MaxCyte STX system.

James Brady, Ph.D.
James Brady, Ph.D., Director Technical Applications at MaxCyte, handles technical inquiries and works with scientists at client companies to ensure that  MaxCyte is able to meet their specialized cell loading needs.  Dr. Brady  received a B.S. in Biology from the College of William and Mary and a Ph.D. in Genetics from Indiana University. He spent eight years as a postdoctoral fellow in the National Eye Institute of the National Institutes of Health. After leaving NIH, Dr. Brady worked at MetaMorphix, Inc. as a Senior Scientist and Group Leader in the Company’s Transgenic Livestock program, where he managed internal and external projects focused on improving livestock by modifying the activity of growth and differentiation factors. Prior to joining MaxCyte, Dr. Brady was a Senior Scientist at Genetic Therapy, Inc., a Novartis subsidiary, where he worked on lentiviral-based gene therapy treatments for ocular disorders.